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Controlled oxygen release from pyridone 
endoperoxides promotes cell survival under anoxic 
conditions  
Sebastian Benz§,‡, Sarah Nötzli#,‡, Jay S. Siegel†,§, Daniel Eberli#,*, Henning J. Jessen§,* 
§ University of Zürich, Institute of Organic Chemistry, Winterthurerstrasse 190, 8057 Zürich, 
Switzerland. # University of Zürich, University Hospital, Department of Urology, 
Frauenklinikstrasse 10, 8091, Zürich, Switzerland. 
ABSTRACT. In tissue engineering, survival of larger constructs remains challenging due to 
limited supply with oxygen caused by a lack of early vascularization. Controlled release of 
oxygen from small organic molecules represents a possible strategy to prevent cell death under 
anoxic conditions. A comprehensive study of methylated pyridone-derived endoperoxides has 
led to the development of water-soluble molecules that undergo retro Diels-Alder reactions in 
aqueous environment releasing oxygen in high yield and with half-lives of up to 13 hours. These 
molecules in combination with vitamin C as singlet oxygen quencher significantly improved 
survival of 3T3 fibroblasts and rat smooth muscle cells challenged with oxygen-depleted 
conditions.   
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INTRODUCTION. The support of anoxic tissue with oxygen to enhance cell survival holds 
promise in different areas of medical research and applications. In regenerative medicine, 
necrosis of engineered tissue as a result of oxygen depletion has remained a challenging 
problem, especially in larger grafts.1-7 The efficiency of oxygen supply in engineered grafts is 
reduced, due to the poor vascularization8-10 of these implants and the diffusion limit of molecular 
oxygen.11 Necrosis and apoptosis of cells in engineered grafts and a shift to anaerobic 
metabolism controlled by hypoxia-inducible factor 1 (HIF-1)12,13 under oxygen-deprived 
conditions can impair the healing process significantly. As a result of coagulative necrosis, cell 
debris and denatured proteins accumulate and further reduce oxygen supply causing failure in 
vital functions of the tissue. Thus, effort has been dedicated to the development of techniques 
that can supply oxygen to hypoxic/anoxic tissue (see notes at the end of the paper).5,14-16 An 
intriguing strategy is the use of (biodegradable) polymers as scaffolds that slowly release oxygen 
in the graft.17-20 The release must occur on a time-scale enabling the growth of a vascular network 
that can eventually support engineered tissue autonomously. From this perspective, the release of 
oxygen should occur over several days.21 The molecules that have been studied in tissue 
engineering of bones and cardiosphere derived stem-cell therapy are hydrogen peroxide, 
sometimes combined with catalase,18 and in the context of pancreatic islet regeneration,20 
inorganic peroxides such as calcium peroxide that eventually produce hydrogen peroxide.22 
Soaking of biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA)23 has led to 
promising results, showcasing the possibility to rescue hypoxic tissue and, as a consequence, 
decrease necrosis of tissue over multiple days in a naked mouse skin flap model.17 However, an 
issue can be the cytotoxicity of the H2O2/catalase mixture or, more general, uncontrolled release 
of oxygen and ions such as Ca2+.24,25 On this account, endoperoxides incorporated into small 
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organic molecules are interesting alternatives owing to their ability to release oxygen in a retro 
Diels-Alder reaction following first order kinetics.26 The reaction rate can likely be controlled by 
the substitution pattern on the scaffold and does not rely on the presence of enzymes or other 
triggers. Moreover, these scaffolds could be attached covalently to a solid support, opening up 
the possibility to synthesize oxygen-releasing polymers with defined rates of oxygen release and 
without soluble byproducts, such as calcium ions. Systems that have been shown to reversibly 
incorporate oxygen are derived from polyaromatic hydrocarbons like e.g. naphthalene and 
anthracene or different 2-pyridones.27-31 The latter provide a scaffold that allows straightforward 
generation of interesting substitution patterns, whilst their polar nature should enhance solubility 
in water as compared to e.g. anthracene-derived endoperoxides. Thus, the controlled release of 
oxygen from substituted 2-pyridone-derived endoperoxides in aqueous environment followed by 
subsequent quenching32 of initially formed 1O2 to 3O2 e.g. by solvent deactivation33 potentially 
provides a new strategy to rescue anoxic tissue from necrosis.   
CHEMISTRY. To study the rate and efficiency of oxygen release from pyridone-derived 
endoperoxides, a series of substituted 2-pyridones had to be obtained and then subjected to type 
two photooxygenations.34 It has been shown in naphthalene-derived endoperoxides, that 
substituting the bridgehead position significantly decreases the rate of the retro Diels-Alder 
reaction.30,35 As one goal was the attenuated release of oxygen to prolong tissue supply and 
reduce oxygen-related toxicity, a series of methylated 2-pyridones was targeted to study the 
effect of simple substituents and combinations thereof in the system. In this context, the yield of 
oxygen release in water is clearly another important parameter. To increase the overall stability 
of the pyridone endoperoxides34 and their solubility in water, a short triethylene glycol ether 
moiety was attached to the pyridone via N-alkylation that strongly reduced lipophilicity (see 
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table 1, ClogP values). As starting materials for the synthesis, some (methylated) 2-pyridones, 
such as 9 and 10, are commercially available, others had to be obtained by chemical 
transformations (see Scheme 1).  
Briefly, 2-bromo-6-methylpyridine 1 was treated with sodium methoxide in methanol under 
microwave irradiation for 1 hour and the intermediate methoxypyridine was directly converted 
into the 6-methyl-2-pyridone 2 with hydrochloric acid in 1,4-dioxane at 100°C in 70% yield over 
both steps.36  
2,5-Lutidine 3 was selectively brominated with one equivalent of tribromoisocyanuric acid 
(TBCA)37 in 20% oleum giving an intermediate dibromide38 in 89% yield after stirring for three 
hours at room temperature. Nucleophilic substitution of bromide with sodium methoxide in 
methanol under microwave irradiation delivered 2-methoxypyridine derivative 4. Lithium 
bromide exchange yielded the 3,6-dimethyl-2-pyridone 5 after protonation of the lithiated 
intermediate with water and cleavage of the methyl ether. Alternatively, reaction of the lithiated 
intermediate with methyl iodide delivered the 3,5,6-trimethyl-2-pyridone39 6 after cleavage of the 
methyl ether.  
3,5-Lutidine 7 was converted with meta-chloroperbenzoic acid into its corresponding N-oxide, 
which was first treated with acetic acid anhydride and then with water at elevated temperature 
giving 3,5-dimethyl-2-pyridone 8.40  
The series of 2-pyridones was N-alkylated with 2-[2-(2-methoxyethoxy)ethoxy]ethyl 2-
bromoacetate.41 Careful adjustment of the reaction conditions for each 2-pyridone was necessary 
to control N- versus O-alkylation.42 The ester moiety was important, as otherwise the 
endoperoxide could not be stably incorporated into the scaffold.34 It should be noticed that this is 
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also a suitable attachment point for covalent linkage to different polymers. The synthetic and 
commercially available 2-pyridones 11-16 were converted into their endoperoxides 17-22 by 
type two photooxygenations using triplet oxygen and tetraphenylporphyrin (TPP) as a sensitizer 
under irradiation with a high-pressure sodium lamp.43,44 The Diels-Alder reactions occurred 
smoothly and with high yield within one hour in DCM at 0 °C. The products were purified by 
flash column chromatography over SiO2. All endoperoxides were stable over a period of many 
months if stored appropriately at -20 °C. 
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Scheme 1. Synthesis of substituted 2-pyridones and their corresponding endoperoxides.a 
 
a Reagents and conditions a) 4 eq. NaOMe, MeOH, microwave 100 °C, 1h; b) HCl conc. / 1,4-
Dioxane, microwave 100 °C, 2h; c) 1 eq. TBCA, Oleum 20% SO3, 2.5h; d) i. 1.1 eq. n-BuLi 
THF, -78°C, ii. H2O, 0 °C to RT; e) i. 1.1 eq. n-BuLi, THF, -78 °C, ii. 3 eq. MeI, -78 °C to RT; f) 
1.1 eq. mCPBA, DCM, RT, 5h; g) i. Ac2O, reflux, 20 h, ii. H2O, reflux, 2h; h) i. 1.1 eq. NaH, 
DME/DMF, 0 °C, 15 min, ii. 2.0 eq. LiBr, RT, 15 min, iii. 2.0 eq 2-[2-(2-
Methoxyethoxy)ethoxy]ethyl 2-bromoacetate, 65 °C, 4-12h; i) 3.0 eq. K2CO3, then 1.5 eq 2-[2-
(2-Methoxyethoxy)ethoxy]ethyl 2-bromoacetate, DMF, overnight, RT; j) TPP cat., hν, DCM, 0 
°C, 1h. 
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BIOLOGY. For the evaluation of cell expansion, 3T3 fibroblast cell line and primary smooth 
muscle cells (SMCs) freshly isolated from rat bladder tissue45 were cultured at a density of 4000 
cells/cm2. Endoperoxide 18 or pyridone 12 was dissolved in a 1:50 H2O/DMSO (DMSO Hybri-
Max®, Sigma, Switzerland) mix and different amounts (10, 50, 100 and 200 µg/mL) were 
directly added to cells in culture medium (CM) consisting of Dulbecco’s modified Eagle 
Medium (DMEM), 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin (DMEM/F-
12, GlutaMAX™ and Pen/Strep, Gibco®; HyClone® FBS Defined, ThermoScientific). Vitamin C 
(Sigma, Switzerland) dissolved in H2O was used in different concentrations as antioxidant (100 
and 500 µg/mL to fibroblasts; 100 and 200 µg/mL to SMCs) and added to the endoperoxide 18 
under the different assay conditions. All experiments were performed in triplicates. Cells with or 
without additives served as controls. Further, the parent pyridone 12 (the other product of the 
retro Diels-Alder process of 18 besides oxygen) was tested with SMCs only. 
All tests were performed in normoxic (aerobic, 37°C, 5% CO2) and anoxic environment (N2). For 
the anoxic condition, CM was degassed prior to use with N2 for 2-3 hours (continuous bubbling 
of N2 through a sterile tube into the medium). The experiments were conducted in an O2-free 
environment by adding nitrogen gas to an airtight bag system (Sekuroka®-Glove-Bags, Carl 
Roth GmbH, Switzerland). Additionally, the 24-well plates were individually packed in airtight 
minigrip bags and kept in the incubator (37°C, 5% CO2) without following medium change for 
up to 4 days. For the aerobic condition, cells were processed in a laminar flow hood and kept in 
the same incubator without airtight sealing. 
Cell viability was measured on days 1-4 using a colorimetric assay with 2-(4-iodophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt reagent (WST-1, Roche, 
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Switzerland) according to the supplier. Briefly, CM was substituted with 0.5 mL/well fresh CM 
containing 50 µL/well WST-1 reagent (1:10). After an incubation time of 3 hours, absorbance of 
the supernatant was measured at 450 nm in a scanning multiwell spectrophotometer (KC4™, 
Software BioTek Instruments, Inc. Luzern, Switzerland). 
RESULTS AND DISCUSSION.  
Chemical behavior in water. The half-lives of the retro Diels-Alder process at 37 °C in H2O / 
D2O 9:1 v/v were measured by 1H-NMR spectroscopy with water suppression assuming first 
order kinetics. Since the chemical shift of the released 2-pyridones was known, quantification of 
oxygen release was possible. The half-lives were estimated by fitting of an exponential 
regression curve and using the equation t1/2 = ln(2)/k (see Scheme 2). The obtained values are 
summarized in the following table 1. 
Scheme 2. Exponential decay of endoperoxide 18 and evolution of parent pyridone 12a in water. 
 
a Values in the graph (left) are normalized on starting endoperoxide 18. The values were obtained 
by integration of explicit proton resonances (right) in the 1H NMR spectrum (H2O/D2O 9:1) and 
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normalized to resonances of a defined amount of added DMSO. The partial 1H NMR spectrum 
shows the distinct signals before (red, 0 h) and after (blue, >60 h) retro-Diels Alder reaction. 
Table 1. ClogP, half-lives and amount of oxygen release from endoperoxides in water at 37°C.  
Compound ClogPa) t 1/2 [h] % retro Diels-Alder 
17 -0.8 0.5 18b) 
18 -0.4 8.5 78b) 
19 -0.4 4 ca. 50c) 
20 0.0 13 47b) 
21 0.0 4 ca. 50c) 
22 0.1 15 ca. 10c) 
a) ChemDraw Pro (Version 12); b) measurement normalized on DMSO standard; c) not 
normalized 
 
For endoperoxides 17, 18 and 20, more precise values were obtained by internal standardization 
with DMSO. Additionally, the NMR studies were used for an evaluation of the selectivity of the 
process, as the chemical shifts of the starting 2-pyridone were known. Thus, peaks arising from 
the retro Diels-Alder process were readily assigned. The 2-pyridone and the endoperoxide that 
had the most favorable properties, i.e. a long half-life combined with a good yield of oxygen and 
little byproduct formation, were then examined in cell assays (vide supra). Non-methylated 
endoperoxide 17 was the least stable in water and decomposed quickly and unspecifically within 
30 minutes at 37 °C. This behavior is in contrast to an earlier publication, where oxygen release 
from a related non-methylated pyridone was measured in chloroform and found to occur slowly 
and selectively.29 Endoperoxide 18 with a methyl group in the 3-position slowly released oxygen 
in water with a half-life of 8 hours with only little byproduct formation (ca. 20%, see Figure 1). 
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Due to its favorable properties, this compound was eventually chosen for the cell-based assays. 
Methylation in the 6-position as in 19, 21, 22 opened up new decomposition pathways other than 
retro Diels-Alder thus increasing byproduct formation (>50%) and decreasing oxygen yield and 
half-lives (ca. 4 h). Compound 20 with methyl groups in the 3- and 5- position displayed an 
increased half-life of about 13 hours and acceptable oxygen yield (50%). The main byproduct in 
most of the cases is the rearranged pyridone resulting from the Kornblum-Delamare 
reaction31,46,47 that is triggered both under basic and acidic conditions (results not shown). From 
these studies it became obvious that modification of the pyridone in the 3 position resulted in 
favorable properties, whereas methylation e.g. in the 6 position strongly reduced the propensity 
of the system to undergo retro Diels-Alder reaction.  
Cell Viability and Cytotoxicity. The properties of endoperoxide 18 were studied in combination 
with rat smooth muscle cells (SMCs) and 3T3 Fibroblasts (FBs). These cell lines play important 
roles in tissue regeneration, as they are constituents of blood vessels and connective tissue, 
respectively.48-50 It is important to notice that their natural environments generally feature 
hypoxic conditions (sometimes referred to as in situ normoxia),51 which might explain the slow 
growth under normoxic, ambient conditions (actually hyperoxia) that was generally observed in 
the assays.52 Interestingly, fibroblasts contain significantly increased VEGF mRNA if grown 
under hypoxic conditions,53 initiating angiogenesis in hypoxic tissue along with other factors.54,55 
Initially, growth of FB and SMC under normoxic and anoxic conditions was followed and 
quantified over four days. The untreated control was normalized to 100% growth rate and 
compared to cells grown in the presence of additives. Increased growth rate was attributed to 
improved survival and avoidance of cell-cycle arrest under the respective conditions.19,56 From 
the experimental setup one would expect the following observations: 1) Under normoxic 
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conditions the endoperoxide should not lead to growth enhancement. 2) High concentrations of 
the endoperoxide should reduce cell viability under normoxic conditions, as singlet oxygen is 
released.57 3) The addition of an antioxidant like vitamin C (physical and chemical quenching of 
1O2)58 should reduce the cytotoxicity exerted by the endoperoxide. 4) Under anoxic conditions 
the endoperoxide should enhance the normalized growth rate of the cells, if used at non-toxic 
concentration. 5) small amounts of endoperoxide could already have an effect on the growth rate, 
as both cell types usually grow under hypoxic conditions. 6) The byproduct of the retro Diels-
Alder process, the corresponding pyridone, should not have an effect on cell growth both under 
normoxic and anoxic conditions.  
Based on the above considerations, the cytotoxicity of the compounds had to be determined first. 
The growth rate was quantified after the indicated periods with a colorimetric assay (WST-1, 
Roche). As expected, the growth rate of both SMCs and FBs was inhibited upon addition of 
endoperoxide 18 in a concentration-dependent manner. Concentrations of 29 µM (10 µg/mL) up 
to 580 µM (200 µg/mL) were analyzed and already at the lowest concentration an effect on cell 
growth was observed under normoxic conditions in both FBs and SMCs (see Graph 2). However, 
this effect was significantly reduced under anoxic conditions in fibroblasts (10 µg/mL 18). 
Intriguingly, addition of vitamin C as singlet oxygen quencher (100 µg / mL) led to significant 
reduction of the cytotoxic effect of endoperoxide 18 under normoxic conditions and completely 
abolished the negative effect of 18 on cell viability under anoxic conditions (see Graph 3). High 
amounts of vitamin C (500 µg / mL) were usually found to be detrimental in the assays (see 
graph 2, grey bars), at least after 2 days of incubation, whereas on the first day this concentration 
pronouncedly increased the rate of cell growth under anoxic conditions (see graph 3, red, green 
and grey bars) and for very high concentrations of 18 and vitamin C also under normoxic 
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conditions (see graph 2, blue and yellow bars). From these data it becomes obvious, that the cells 
react very differently to the application of endoperoxide 18 under normoxic and anoxic 
conditions. Given the fact that 100 µg / mL of vitamin C did not significantly alter the growth 
rate of cells alone under anoxic conditions (graph 3, light grey bars), this amount was used in the 
following experiments to distinguish the effect exerted by oxygen release from the endoperoxide. 
Graph 2. Normalized growth rate of Fibroblasts under normoxic conditions  
 
Fibroblasts grown under normoxic conditions over 4 days. The growth rate without additives 
(black bars) was normalized to 100%. Addition of different concentrations of endoperoxide 18 
(EP18) without or with vitamin C (C). The colors indicate one set of experiments at one fixed 
concentration of 18 (EP18). Vitamin C alone (grey bars) served as control. In general, all 
additives were detrimental for cell growth except high concentrations on vitamin C and 18 (blue 
bars, only on the first day). Read legend as follows: EP18 10 C500, endoperoxide 18 at 10 
µg/mL + 500 µg/mL vitamin C. 
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Graph 3. Normalized growth rate of Fibroblasts under anoxic conditions  
 
Fibroblasts grown under anoxic conditions over 4 days. The growth rate without additives was 
normalized to 100%. Addition of different concentrations of endoperoxide 18 (EP18) without or 
with vitamin C (C). The colors indicate one set of experiments at one fixed concentration of 18 
(EP18). Vitamin C alone (grey bars) served as control. Addition of vitamin C (100 µg / mL) 
reduced cytotoxicity of 18 and a significant effect on cell growth was observed on day 1 (red 
bars). For the following days 2-4 cell growth was reduced to normal levels again. Read legend as 
follows: EP18 10 C500, endoperoxide 18 at 10 µg/mL + 500 µg/mL vitamin C. 
Next, it was important to find out the optimal concentration range of the endoperoxide 18 in the 
presence of vitamin C. 100 µg / mL 18 were still found to reduce cell viability by a factor of ca. 
10 in FBs in the presence of vitamin C under normoxic conditions (Graph 2, blue bars, day 4), 
whereas under anoxic conditions the viability was only impaired by a factor of 2 (Graph 3, blue 
bars, day 4). If 200 µg / mL 18 were used, no beneficial effect of vitamin C could be observed 
anymore (Graph 2 and 3, yellow bars). The cytotoxicity of 18 at 50 µg / mL was still 
considerable even in the presence of vitamin C (Graph 2 and 3, green bars). The best results were 
obtained with 10 µg / mL of endoperoxide 18 in the presence of 100 µg / mL vitamin C (Graph 2 
and 3, red bars).  
 14 
Under anoxic conditions the combination of endoperoxide 18 (10 µg / mL) with vitamin C (100 
µg / mL) displayed no cytotoxicity in FBs but a significant beneficial effect on day 1 (graph 3, 
red bars).  
For SMCs, a similar picture was obtained. Under normoxic conditions SMC growth rate was 
impaired starting from a concentration of 50 µg / mL endoperoxide 18. This cytotoxicity of 18 
was much less pronounced in SMCs as compared to FBs. Vitamin C alone (100 and 200 µg / 
mL) had neither a beneficial nor detrimental effect on cell growth (graph 4, grey bars) but 
enhanced cell survival in the presence of endoperoxide 18 at 50 µg / mL (graph 4, green bars). 
As a control, the parent pyridone 12 that is also released in the retro Diels-Alder reaction did not 
show a beneficial effect on cell growth (graph 4, orange bars). 
Strikingly, SMCs showed increased cell growth under anoxic conditions even over 4 days in the 
presence of endoperoxide 18 (10 µg / mL) and vitamin C (100 µg / mL) as compared to the 
control experiment and normoxic conditions (graph 5, red bars, shown in more detail in graph 6). 
Endoperoxide 18 alone did not have this significant effect, likely counterbalancing the 
cytotoxicity of singlet oxygen. Also at 50 µg / mL 18 the beneficial effect of O2 release was 
counterbalanced by the cytotoxicity at this concentration, which is also valid for high amounts of 
vitamin C (200 µg / mL). Pyridone 12 (50 µg / mL) in the presence of vitamin C did not increase 
cell survival over four days significantly (graph 5, orange bars) and was nontoxic up to 
concentrations of 100 µg / mL if tested alone (data not shown).  
In summary, pyridone endoperoxide 18 in the presence of vitamin C can supply cells under 
anoxic conditions with O2 and increase survival over extended periods of time. 
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Graph 4. Normalized growth rate of smooth muscle cells under normoxic conditions  
 
Smooth muscle cells grown under normoxic conditions over 4 days. The growth rate without 
additives was normalized to 100%. Addition of two different concentrations of endoperoxide 18 
(EP18) without or with vitamin C. The colors indicate one set of experiments at one fixed 
concentration of 18 (EP18). Vitamin C (C) alone (grey bars) served as control. Pyridone 12 at 10 
µg / mL (Pyr12) served as a negative control (orange bars) and had no beneficial effect on cell 
growth in the presence or absence of vitamin C (C). Read legend as follows: EP18 10 C100, 
endoperoxide 18 at 10 µg/mL + 100 µg/mL vitamin C. 
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Graph 5. Normalized growth rate of smooth muscle cells under anoxic conditions  
 
Smooth muscle cells grown under anoxic conditions over 4 days. The growth rate without 
additives was normalized to 100%. Addition of different concentrations of endoperoxide 18 
(EP18) without or with vitamin C (C). The colors indicate one set of experiments at one fixed 
concentration of 18 (EP18). Vitamin C alone (grey bars) served as control. Addition of vitamin C 
(100 µg / mL) and 18 resulted in a significant effect on cell growth over 4 days (dark red bars). 
Pyridone 12 (Pyr12) served as a negative control. Read legend as follows: EP18 10 C100, 
endoperoxide 18 at 10 µg/mL + 100 µg/mL vitamin C.  
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Graph 6. Normalized growth rate of smooth muscle cells under anoxic conditions  
 
 Smooth muscle cells grown under anoxic conditions over 4 days. A clear beneficial effect of 
endoperoxide 18 (EP18) on growth rate in the presence of vitamin C (100 µg / mL) was observed 
over 4 days. Read legend as follows: EP18 10 C100, endoperoxide 18 at 10 µg/mL + 100 µg/mL 
vitamin C.  
1O2 release. Given a molar volume of 24 L/mol at 25°C of O2, in principle an 80% retro Diels 
Alder reaction of 10 µg endoperoxide 18 can release 600 nL of oxygen. To further support the 
idea of initial singlet oxygen release from the pyridone endoperoxide 18, the singlet oxygen 
sensor green® assay from Invitrogen was applied. Briefly, a singlet oxygen responsive moiety 
attached to a fluorophore and quenching its fluorescence is the basis of this assay. After reaction 
of the responsive moiety with singlet oxygen, the emission of the fluorophore is restored, 
allowing fluorimetric readout.59 Graph 7 shows the results of the experiments conducted in the 
presence and absence of vitamin C. From the data it becomes obvious, that pyridone 
endoperoxide 18 releases singlet oxygen and that addition of vitamin C efficiently quenches the 
released singlet oxygen.  
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Graph 7. SOSG assay® to detect singlet oxygen released from endoperoxide 18   
 
Singlet oxygen sensor green® (SOSG) detects singlet oxygen released from pyridone 
endoperoxide 18 (EP18) in water at 37 °C (blue dots). Fluorescence was monitored with the 
exitation/emission pair 488/525 nm. In the presence of vitamin C, no singlet oxygen is detected 
anymore (orange dots).   
CONCLUSION. While in many studies involving oxygen generation cytotoxicity of a compound 
is the ultimate goal, as e.g. in cancer research,60,61 the support of damaged tissue with small 
organic molecules is a largely unexplored area. In tissue engineering, survival of the grafts is 
critical and failure in sufficient oxygen supply can lead to necrosis. Usually, poor vascularization 
is one severe problem in larger grafts. Hypoxic conditions are generally well tolerated by cells as 
reduced oxygen pressure can be found in most tissues. However, anoxic conditions can have 
devastating effects on cell survival. Thus, it is likely that already minute amounts of oxygen can 
rescue anoxic tissue from necrosis. Moreover, fibroblasts entering hypoxic tissue have increased 
amounts of mRNA encoding vascular endothelial growth factor (VEGF) an important signaling 
protein in vasculogenesis and angiogenesis.  
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In this study, fibroblasts and smooth muscle cells were grown under normoxic (21% O2) and 
anoxic (0% O2) conditions in the presence of water-soluble pyridone endoperoxides. The 
endoperoxide used in the assays was optimized towards long half-life in water (8 h to 13 h) and 
efficient retro Diels Alder reaction (ca. 80%), releasing (singlet) oxygen. The cytotoxicity of the 
released singlet oxygen was controlled by addition of vitamin C. Efficient quenching of singlet 
oxygen by vitamin C was demonstrated by applying the singlet oxygen sensor green assay. The 
cell studies clearly show a reduction of the cytotoxicity of endoperoxides in the presence of 
vitamin C. Moreover, FBs showed increased growth rate under anoxic conditions on the first day 
of the study and SMCs had increased growth rates over 4 days as compared to the controls. Thus, 
pyridone endoperoxides efficiently release oxygen under cell culture conditions and can rescue 
cell growth under strictly anoxic conditions in two important cell lines responsible for early 
vascularization. It should be possible to covalently attach these molecules to polymeric scaffolds, 
thus enabling the generation of oxygen releasing polymers that can be used in tissue engineering. 
The endoperoxides, either in free form or attached to bandages could in principle be used to 
support necrotic wounds with oxygen. The efficiency in the latter process will be studied in a 
mouse skin flap model in due course.  
EXPERIMENTAL SECTION.  
Synthesis. Chemicals were purchased from commercial suppliers (Acros, Aldrich, TCI) and used 
without further purification, unless noted otherwise. Deuterated solvents were obtained from 
Armar Chemicals, Switzerland, in the indicated purity grade. 1H NMR spectra were recorded on 
Bruker 300 & 400 MHz spectrometers, Bruker 500 MHz spectrometers (equipped with a cryo 
platform) at 298K in the indicated deuterated solvent. Data are reported as follow: chemical shift 
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(δ, ppm), multiplicity (s, singulet; d, doublet; t, triplet; q, quartet; m, multiplet or not resolved 
signal; br, broad signal), coupling constant(s) (J, Hz), integration. All signals were referenced to 
the internal solvent signal as standard (CDCl3, δ 7.26; D2O, δ	  4.79; CD3OD, δ	  3.31; DMSO-d6, δ 
2.50). 13C-NMR spectra were recorded with 1H-decoupling on Bruker 75, 101 MHz or Bruker 
125 MHz spectrometers (equipped with a cryo platform) at 298K in the indicated deuterated 
solvent. All signals were referenced to the internal solvent signal as standard (CDCl3, δ	  77.16, 
CD3OD, δ	  49.0; DMSO-d6, δ	  39.5). IR Spectra were recorded on a JASCO FT-IR-4100 
spectrometer and data are reported in terms of frequency of absorption (cm-1). 
Microwave experiments were conducted on a CEM Discover microwave (300 Watt, 10 mL Tube 
volume). 
Mass spectra were recorded by the Mass spectroscopy Service of UZH on Finnigan MAT95 MS, 
Bruker EsquireLC MS , Bruker maXis QTof HR MS and Finnigan TSQ700 MS machines. For 
thin layer chromatography (TLC) Merck precoated 60 F254 plates with a 0.2 mm layer of silica 
gel were used. For column chromatography, Merck silica gel 60, 230-400 mesh was used. The 
purity of the compounds was additionally checked by HPLC analysis (CN modified silica, 
elution with hexane/iprOH gradient) and found to be >95% unless indicated otherwise.  
Fluorescence Measurements.  One vial of singlet oxygen sensor green® (Invitrogen), was 
dissolved in 33 µL MeOH. The endoperoxide was dissolved in 10 µL MeOH and diluted with 
water to the desired concentrations. Vitamin C was dissolved only in water. 200 µL of total 
volume was introduced into a black 96-well plate (Greiner Bio One) and covered with a 
transparent plastic foil. The plate was placed into a plate reader (Spectra Max M5, Molecular 
Devices) and every 10 minutes a value was recorded at 37 °C (excitation/emission 488/525 nm). 
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All measurements were conducted in triplicate. Blank measurements containing SOSG and 
SOSG/vitamin C were subtracted from the results.  
6-Methyl-2-pyridone 2. 2-Bromo-6-methylpyridine 1 (500 mg, 2.90 mmol) and freshly prepared 
sodium methoxide (313 mg, 5.80 mmol) were dissolved in MeOH (4 mL) and heated in the 
microwave for 1 h at 105 °C. The mixture was concentrated under reduced pressure, extracted 
with diethyl ether and washed with water. The organic layer was concentrated in vacuo. HCl 
32% (1.5 mL) and 1,4-dioxane (2 mL) were added and the solution heated in the microwave for 
2 h at 100 °C. The reaction mixture was concentrated in vacuo, dissolved in DCM and washed 
with water. The organic layer was dried with MgSO4 and concentrated to yield the title 
compound as a colorless solid (220 mg, 2.02 mmol, 70%). 
1H NMR (400 MHz, CDCl3) δ 13.57-12.19 (bs, 1H), 7.38 (dd, J = 9.1, 6.9 Hz, 1H), 6.43 (d, J = 
9.1 Hz, 1H), 6.09 (d, J = 6.9 Hz, 1H), 2.37 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 166.2, 146.1, 
142.1, 116.5, 106.2, 19.1; HRMS (ESI) calcd for C6H7NNaO [M]+ 132.04198, found 132.04192. 
2,5-Dibromo-3,6-dimethylpyridine. Oleum (20% in water, 20 mL) was cooled to 0 °C and 2,5-
lutidine 3 (1.50 g, 14.0 mmol) was added slowly. After warming to room temperature, TBCA 
(5.12 g, 14.0 mmol) was added in 1 g portions over a period of 2.5 h to the stirred solution. The 
reaction mixture was poured on ice water (80 mL), neutralized with sodium carbonate and 
extracted with diethylether. The organic layer was dried over magnesium sulfate and evaporated 
to give the title compound as a colorless solid (3.30 g, 12.5 mmol, 89%). This material was used 
in the next step without further purification. 
1H NMR (300 MHz, CDCl3) δ 7.62 (s, 1H), 2.60 (s, 3H), 2.33 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 155.6, 142.1, 142.0, 134.1, 120.2, 24.1, 21.3; HRMS (ESI) calcd for C7H7Br2N [M]+ 
263.90180, found 263.90167. 
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3-Bromo-2-methoxy-3,6-dimethylpyridine 4. 2,5-Dibromo-3,6-dimethylpyridine (3.00 g, 11.3 
mmol) was added to freshly prepared sodium methoxide (2.45 g, 45.3 mmol) in MeOH (12 mL), 
devided in to three equal portions and irradiated in the microwave at 100°C for 1h. The mixtures 
were combined, concentrated in vacuo and redissolved in EtOAc and water. The organic layer 
was washed with brine, dried over magnesium sulfate and concentrated in vacuo. The residue 
was diluted with hexane and a white solid was filtered off. The filtrate was concentrated to give 
the product as a clear liquid (2.10 g, 9.72 mmol, 89%). The product was used in the next step 
without further purification. 
1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 3.91 (s, 3H), 2.50 (s, 3H), 2.12 (s, 3H); 13C NMR 
(126 MHz, CDCl3) δ 160.7, 151.1, 141.7, 119.9, 111.4, 53.6, 24.0, 15.3; IR νmax/cm-1 2948, 1569, 
1459, 1356, 1313, 1246, 1174, 1036, 962; HRMS (ESI) calcd for C8H11BrNO [M]+ 216.00185, 
found 216.00168 
3,6-Dimethyl-2-pyridone 5. Pyridine 4 (700 mg, 3.23 mmol) was dissolved in 10 mL dry THF 
and cooled to -78 °C. To this solution was slowly added n-BuLi (2.5 M in hexane, 1.43 mL, 3.56 
mmol) and after stirring for 2.5 h the mixture was warmed to 0 °C and H2O (1.5 mL) was added 
carefully. The solution was concentrated in vacuo. HCl 32% (2.5 mL) and 1,4-dioxane (2 mL) 
were added and the solution heated in the microwave at 100 °C for 2 h. The mixture was 
neutralized with sodium carbonate and extracted with ethyl acetate, washed with brine and 
concentrated in vacuo. Purification by flash chromatography (9:1 DCM/MeOH v/v) yielded the 
title compound as a colorless solid (270 mg, 2.19 mmol, 68%).  
Melting point 173-175°C; 1H NMR (500 MHz, CDCl3) δ 12.90-12.26 (bs, 1H), 7.19 (d, J = 6.9 
Hz, 1H), 5.95 (d, J = 6.9 Hz, 1H), 2.32 (s, 3H), 2.11 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
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165.7, 142.7, 139.4, 125.4, 105.7, 18.9, 16.3; IR νmax/cm-1 2924, 1642, 1580, 1480, 593; HRMS 
(ESI) calcd for C7H9NNaO [M+Na]+ 146.05764, found 146.05776. 
3,5,6-Trimethyl-2-pyridone 6. Pyridine 4 (700 mg, 3.23 mmol) was dissolved in 10 mL dry 
THF and cooled to -78 °C. To this solution was slowly added n-BuLi (2.5M in hexane, 1.43 mL, 
3.56 mmol). After stirring for 2.5 h, methyl iodide (1.38 g, 9.73 mmol) was added and the 
mixture was warmed to room temperature. The solution was stirred for 50 min, concentrated in 
vacuo and dissolved in HCl 32% (1.5 mL) and 1,4-dioxane (2 mL). The mixture was heated in 
the microwave for 1.5 h at 100 °C, concentrated in vacuo and extracted with DCM. The organic 
layer was washed with sat. sodium carbonate, sat. ammonium chloride, 1 M sodium thiosulfate 
and brine. The organic layer was dried over MgSO4 and concentrated in vacuo. Purification by 
flash chromatography (9:1 DCM/MeOH v/v) yielded the title compound as an off-white solid 
(310 mg, 2.26 mmol, 70%). 
1H NMR (400 MHz, CDCl3) δ 12.7-11.28 (bs, 1H), 7.12 (s, 1H), 2.26 (s, 3H), 2.11 (s, 3H), 2.02 
(s, 3H); 13C NMR (126 MHz, CDCl3) δ 164.9, 142.7, 139.1, 125.0, 112.5, 16.7, 16.2, 16.1; 
HRMS (ESI) calcd for C8H12NO [M]+ 138.09134, found 138.09143. 
3,5-Dimethylpyridine-N-oxide. 3,5-Dimethylpyridine 7 (3.00 g, 28.0 mmol) was dissolved in 
DCM (50 mL) and cooled to 0 °C. mCPBA (75% stabilized with water, 7.00 g, 30.8 mmol) was 
added in 3 portions over a period of 10 min. The solution was warmed to room temperature, 
stirred for 5 h. The organic layer was mixed with sat. NaHCO3 and extracted four times with 
DCM. The combined organic layers were dried over MgSO4 and concentrated in vacuo to yield 
the product as a colorless solid (2.10 g, 17.0 mmol, 61%). 
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1H NMR (300 MHz, CDCl3) δ 7.95 (s, 2H), 6.95 (s, 1H), 2.27 (s, 6H); 13C NMR (126 MHz, 
CDCl3) δ 136.5, 136.0, 129.0, 18.1.; HRMS (ESI) calcd for C7H10NO [M]+ 124.07569, found 
124.07562. 
3,5-Dimethyl-2-pyridone 8. 3,5-Dimethylpyridine-N-oxide (2.10 g, 17.0 mmol) was dissolved 
in acetic acid anhydride (30 ml) and heated under reflux for 20 h. The solution was concentrated 
in vacuo. Water (25 mL) was added and the resulting mixture was heated under reflux for 2 h. 
The mixture was concentrated in vacuo and dried by repeated azeotropic distilliation with 
toluene. Purification by flash chromatography (9:1 DCM/MeOH v/v) yielded the title compound 
as an off-white solid (0.80 g, 6.5 mmol, 38%).  
Melting point 86-89 °C; 1H NMR (300 MHz, CDCl3) δ 12.67-11.95 (bs, 1H), 7.19 (d, J = 1.1 Hz, 
1H), 7.04 (s, 1H), 2.15 (s, 3H), 2.06 (d, J = 0.8 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 164.6, 
142.0, 129.6, 128.5, 115.9, 17.1, 16.7; IR νmax/cm-1 3390, 1656, 1630, 1563,1472, 1375, 964, 
881, 701; HRMS (ESI) calcd for C7H10NO [M]+ 124.07569, found 124.07569. 
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-bromoacetate.41 Bromoacetic acid (5.00 g, 36.0 mmol), 
triethylenglycol monomethylether (5.61 g, 34.2 mmol) and a catalytic amount 
dimethylaminopyridine (DMAP, 50 mg) were dissolved in DCM (200 mL) and cooled to 0 °C. 
Dicyclohexylcarbodiimide (DCC, 8.17 g, 39.6 mmol) was slowly added. The mixture was 
warmed to room temperature and stirred overnight. The white precipitate was filtered off and the 
filtrate was concentrated in vacuo. The precipitation/filtration process was repeated once more. 
Purification by flash chromatography (20:1 DCM/MeOH) gave the product as a colorless liquid 
(5.10 g, 52%). 
1H NMR (300 MHz, CDCl3) δ 4.31 – 4.23 (m, 2H), 3.83 (s, 2H), 3.71 – 3.65 (m, 2H), 3.64 – 
3.54 (m, 6H), 3.53 – 3.45 (m, 2H), 3.32 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 167.2, 71.9, 70.6, 
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70.5, 70.5, 68.7, 65.3, 59.0, 25.8; HRMS (ESI) calcd for C9H17BrNaO5 [M+Na]+ 307.0152, found 
307.0154. 
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-(2-oxo-1,2-dihydropyridin-1-yl)acetate 11. 2-pyridone 
(100 mg, 1.05 mmol) was alkylated according to the same procedure described for product 13 
(see below). Yield: 239 mg (0.798 mmol, 76%, colorless oil).1H NMR (400 MHz, CDCl3) δ 7.26 
– 7.20 (m, 1H), 7.19 – 7.13 (m, 1H), 6.41 (d, J = 9.1 Hz, 1H), 6.06 (td, J = 6.7, 1.3 Hz, 1H), 4.55 
(s, 2H), 4.23 – 4.12 (m, 2H), 3.63 – 3.53 (m, 2H), 3.53 – 3.44 (m, 6H), 3.44 – 3.34 (m, 2H), 3.22 
(s, 3H); 13C NMR (101 MHz, CDCl3) δ 167.5, 162.1, 140.1, 138.1, 120.4, 105.9, 71.6, 70.3, 70.3, 
70.2, 68.5, 64.5, 58.7, 50.1; IR νmax/cm-1 1748, 1660, 1540,1197, 1097; HRMS (ESI) calculated 
for C14H21NNaO6 [M+Na]+ 322.12611, found 322.12655. 
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-(3-methyl-2-oxo-1,2-dihydropyridin-1-yl)acetate 12. 
3-Methyl-2-pyridone 10 (200 mg, 1.83 mmol), 2-[2-(2-methoxyethoxy)ethoxy]ethyl 2-
bromoacetate (784 mg, 2.75 mmol) and potassium carbonate (760 mg, 5.50 mmol) were 
dissolved in DMF (20 mL) at room temperature and the solution was stirred overnight. The 
mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with 
water. The organic layer was dried over MgSO4 and concentrated in vacuo. Purification by flash 
chromatography (9:1 DCM/ MeOH v/v) yielded the title compound as a colorless oil (200 mg, 
0.64 mmol, 35 %). 
1H NMR (400 MHz, CDCl3) δ 7.21 – 7.16 (m, 1H), 7.11 – 7.06 (m, 1H), 6.08 (t, J = 6.8 Hz, 
1H), 4.63 (s, 2H), 4.34 – 4.19 (m, 2H), 3.72 – 3.45 (m, 10H), 3.33 (s, 3H), 2.10 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 168.0, 163.0, 137.5, 135.4, 130.0, 106.0, 72.0, 70.6, 70.6, 70.6, 68.9, 
64.8, 59.1, 50.8, 17.2; IR νmax/cm-1 1748, 1652, 1592, 1561, 1196, 1099, 768; HRMS (ESI) 
calculated for C15H23NNaO6 [M+Na]+ 336.14176, found 336.14193. 
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2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-(6-methyl-2-oxo-1,2-dihydropyridin-1-yl)acetate 13. 
6-Methyl-2-pyridone 2 (50 mg, 0.46 mmol), dissolved in 10 mL DME, was cooled to 0 °C and 
NaH (60% suspension in oil, 19 mg, 0.48 mmol) was added. After stirring for 10 min, LiBr (80 
mg, 0.92 mmol) was added and the mixture was stirred for 20 min. 2-[2-(2-
methoxyethoxy)ethoxy]ethyl 2-bromoacetate (157 mg, 0.55 mmol) was added. The mixture was 
heated to 60 °C for 4h, cooled to room temperature and filtered. The filtrate was concentrated in 
vacuo. Purification by flash chromatography yielded the desired product as a colorless oil (40 
mg, 0.13 mmol, 28%). 
1H NMR (300 MHz, CDCl3) δ 7.18 (dd, J = 9.2, 6.8 Hz, 1H), 6.38 (d, J = 9.2 Hz, 1H), 5.98 (d, J 
= 6.7 Hz, 1H), 4.77 (s, 2H), 4.33 – 4.17 (m, 2H), 3.75 – 3.41 (m, 10H), 3.30 (s, 3H), 2.22 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 167.9, 163.3, 145.8, 139.5, 117.4, 106.7, 71.8, 70.5, 70.5, 70.4, 
68.7, 64.6, 58.9, 45.3, 20.4; IR νmax/cm-1 1746, 1660, 1550, 1197, 1099, 794; HRMS (ESI) calcd 
for C15H23NNaO6 [M+Na]+ 336.1418, found 336.1421. 
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-(3,5-dimethyl-2-oxo-1,2-dihydropyridin-1-yl)acetate 
14. 3,5-Dimethyl-2-pyridone 8 (100 mg, 0.810 mmol) was alkylated according to the same 
procedure described for product 13. Yield: 132 mg (0.404, 50%, colorless oil). 
1H NMR (400 MHz, CDCl3) δ 7.08 (d, J = 1.1 Hz, 1H), 6.85 (s, 1H), 4.61 (s, 2H), 4.36 – 4.24 
(m, 2H), 3.73 – 3.67 (m, 2H), 3.66 – 3.59 (m, 6H), 3.57 – 3.49 (m, 2H), 3.35 (s, 3H), 2.10 (s, 
3H), 2.02 (d, J = 0.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.2, 162.2, 140.4, 132.6, 129.4, 
114.8, 72.0, 70.7, 70.7, 70.6, 68.9, 64.79, 59.1, 50.7, 17.2, 17.1; IR νmax/cm-1 1747, 1664, 1593, 
1195, 1100, 1036; HRMS (ESI) calcd for C16H25NNaO6 [M+Na]+ 350.1574, found 350.1579 
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2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-(3,6-dimethyl-2-oxo-1,2-dihydropyridin-1-yl)acetate 
15. 3,6-Dimethyl-2-pyridone 5 (100 mg, 0.81 mmol) was dissolved in DME (9 mL) and cooled 
to -20 °C. n-BuLi (2.5 M in hexane, 0.36 mL, 0.89 mmol) was slowly added under an argon 
atmosphere and the solution stirred for 20 min. 2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-
bromoacetate (347 mg, 1.22 mmol) in DME (0.5 mL) was added, the mixture was warmed to 
room temperature and stirred over night. Concentration under reduced pressure and purification 
by flash chromatography (9:1 DCM/MeOH v/v) yielded the product as a colorless oil (108 mg, 
0.33 mmol, 41%). 
1H NMR (300 MHz, CDCl3) δ 7.12 (dd, J = 6.9, 0.9 Hz, 1H), 5.98 (d, J = 6.9 Hz, 1H), 4.84 (s, 
2H), 4.40 – 4.29 (m, 2H), 3.80 – 3.49 (m, 10H), 3.38 (s, 3H), 2.26 (s, 3H), 2.11 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 168.3, 163.8, 142.7, 137.0, 126.3, 106.4, 72.0, 70.7, 70.6, 70.6, 69.0, 
64.7, 59.1, 45.8, 20.4, 17.1; IR νmax/cm-1 1747, 1651, 1568, 1194, 1101; HRMS (ESI) calcd for 
C16H25NNaO6 [M+Na]+ 364.1731, found 364.1733. 
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-(3,5,6-trimethyl-2-oxo-1,2-dihydropyridin-1-
yl)acetate 16. 3,5,6-Trimethyl-2-pyridone 6 (90 mg, 0.66 mmol) was dissolved in a mixture of 
dry DME (6 mL) and dry DMF (1.5 mL). Under a nitrogen atmosphere the solution was cooled 
to 0 °C, sodium hydride (60% in oil, 28 mg, 0.69 mmol) was added and the solution stirred for 
15 min. To this mixture LiBr (114 mg, 1.31 mmol) was added. The solution was warmed to 
room temperature and stirred for 15 min. 2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-bromoacetate 
(374 mg, 1.31 mmol) was added and the reaction mixture was heated to 65°C overnight. 
Concentration under reduced pressure followed by purification by flash chromatography (9:1 
DCM/MeOH v/v) yielded the product as a colorless oil (150 mg, 0.44 mmol, 67%), purity >85%. 
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1H NMR (400 MHz, CDCl3) δ 7.04 (s, 1H), 4.87 (s, 2H), 4.36 – 4.23 (m, 2H), 3.71 – 3.65 (m, 
2H), 3.65 – 3.57 (m, 6H), 3.55 – 3.47 (m, 2H), 3.34 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 168.6, 
163.1, 141.1, 138.9, 125.6, 112.4, 72.0, 70.6, 70.6, 70.6, 68.9, 64.6, 59.1, 46.0, 18.0, 16.9, 16.4; 
νmax/cm-1 1746, 1639, 1196, 1098; HRMS (ESI) calcd for C17H27NNaO6 [M+Na]+ 350.1574, 
found 350.1577. 
General procedure for the photooxygenation of 2-pyridones. The respective pyridone was 
dissolved in ca. 10 mL DCM in a reaction tube, TPP (1 mg) was added and oxygen was bubbled 
through the solution with vigorous stirring for 5 min. The mixture was kept under an oxygen 
atmosphere with a balloon and cooled to 0°C and irradiated for 1 h with a high-pressure sodium 
lamp. The solution was concentrated in vacuo and the residue was purified by flash column 
chromatography.  
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-{6-oxo-2,3-dioxa-5-azabicyclo[2.2.2]oct-7-en-5-
yl}acetate 17. Pyridone 11 (85 mg, 0.28 mmol); flash chromatography (20:1 DCM/MeOH v/v) 
yielded the endoperoxide 17 as a clear oil (90 mg, 271 mmol, 95%) 1H NMR (400 MHz, CDCl3) 
δ 6.96 – 6.89 (m, 1H), 6.73 – 6.66 (m, 1H), 5.81 – 5.77 (m, 1H), 5.01 – 4.96 (m, 1H), 4.63 (d, J 
= 18.1 Hz, 1H), 4.34 – 4.17 (m, 2H), 3.90 (d, J = 18.1 Hz, 1H), 3.74 – 3.43 (m, 10H), 3.33 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 168.7, 168.0, 135.2, 127.7, 84.5, 77.8, 71.9, 70.5,70.5, 70.5, 
68.6, 64.6, 59.0, 43.9; IR νmax/cm-1 1744, 1704, 1447, 1202, 1098, 891; HRMS (ESI) calculated 
for C14H21NNaO8 [M+Na]+ 354.11594, found 354.11597. 
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-{1-methyl-6-oxo-2,3-dioxa-5-azabicyclo[2.2.2]oct-7-
en-5-yl}acetate 18. Pyridone 12 (90 mg, 0.29 mmol); flash chromatography (20:1 DCM/MeOH 
v/v) yielded the endoperoxide 18 as a slightly purple oil (70 mg, 0.20 mmol, 70%). 
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1H NMR (300 MHz, CDCl3) δ 6.95 (dd, J = 7.8, 5.3 Hz, 1H), 6.45 (dd, J = 7.8, 1.8 Hz, 1H), 5.75 
(dd, J = 5.3, 1.8 Hz, 1H), 4.72 (d, J = 18.1 Hz, 1H), 4.39 – 4.20 (m, 2H), 3.92 (d, J = 18.1 Hz, 
1H), 3.75 – 3.49 (m, 10H), 3.38 (s, 3H), 1.62 (s, 3H), 1.56 (s, 3H); 4.20 (m, 2H), 3.92 (d, J = 
18.1 Hz, 1H), 3.75 – 3.49 (m, 10H), 3.38 (s, 3H), 1.62 (s, 3H), 1.56 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 169.6, 168.8, 134.7, 132.5, 84.7, 81.3, 71.8, 70.5, 70.5, 70.5, 68.6, 64.5, 59.0, 44.2, 
14.5; IR νmax/cm-1 1747, 1705, 1448, 1201, 1104; HRMS (ESI) calcd for C15H23NNaO8 [M+Na]+ 
368.1316, found 368.1316; Rt = 4.9 min (CN modified silica, 10% iprOH in hexanes, isocratic, 1 
mL/min, then gradient to 40% iprOH at 35 min, purity >95%) 
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-{4-methyl-6-oxo-2,3-dioxa-5-azabicyclo[2.2.2]oct-7-
en-5-yl}acetate 19.  Pyridone 13 (40 mg, 0.13 mmol); flash chromatography (20:1 DCM/MeOH 
v/v) yielded the endoperoxide 19 as a clear oil (42 mg, 0.12 mmol, 95%). 
1H NMR (400 MHz, CDCl3) δ 6.72 – 6.65 (m, 2H), 4.98 (dd, J = 4.5, 3.3 Hz, 1H), 4.60 (d, J = 
18.2 Hz, 1H), 4.33 – 4.15 (m, 2H), 3.94 (d, J = 18.2 Hz, 1H), 3.73 – 3.45 (m, 10H), 3.34 (s, 3H), 
1.70 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 169.2, 168.9, 140.0, 126.8, 89.2, 77.2, 72.0, 70.6, 
70.6, 70.6, 68.8, 64.6, 59.1, 40.8, 17.0; IR νmax/cm-1 1744, 1703, 1400, 1196, 1100, 782; HRMS 
(ESI) C15H23NNaO8 [M+Na]+ 368.1316, found 368.1315. 
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-{1,8-dimethyl-6-oxo-2,3-dioxa-5-azabicyclo[2.2.2]  
oct-7-en-5-yl}acetate 20. Pyridone 14 (100 mg, 0.305 mmol); flash chromatography (20:1 
DCM/MeOH v/v) yielded the endoperoxide 20 as a clear oil (82 mg, 0.23 mmol, 75%). 
1H NMR (400 MHz, CDCl3) δ 6.03 – 5.99 (m, 1H), 5.48 (d, J = 2.1 Hz, 1H), 4.74 (d, J = 18.1 
Hz, 1H), 4.30 – 4.25 (m, 2H), 3.85 (d, J = 18.2 Hz, 1H), 3.68 (t, J = 4.7 Hz, 2H), 3.64 – 3.58 (m, 
6H), 3.56 – 3.48 (m, J = 5.7, 3.6 Hz, 2H), 3.35 (s, 3H), 2.07 (d, J = 1.8 Hz, 3H), 1.54 (s, 3H13C 
NMR (101 MHz, CDCl3) δ 170.0, 169.1, 145.7, 125.4, 88.9, 81.5, 72.0, 70.7, 70.7, 70.7, 68.8, 
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64.7, 59.1, 44.0, 17.6, 14.6; IR νmax/cm-1 1745, 1705, 1446, 1200, 1101; HRMS (ESI) calcd for 
C16H25NNaO8 [M+Na]+ 382.1472, found 382.1473. 
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-{1,4-dimethyl-6-oxo-2,3-dioxa-5-azabicyclo[2.2.2]  
oct-7-en-5-yl}acetate 21. Pyridone 15 (60 mg, 0.18 mmol); flash chromatography (20:1 
DCM/MeOH v/v) yielded the endoperoxide 21 as a clear oil (64 mg, 0.18 mmol, 97%), purity 
>90%. 
1H NMR (400 MHz, CDCl3) δ 6.66 (d, J = 7.8 Hz, 1H), 6.38 (d, J = 7.8 Hz, 1H), 4.60 (d, J = 
18.2 Hz, 1H), 4.32 – 4.16 (m, 2H), 3.94 (d, J = 18.2 Hz, 1H), 3.71 – 3.46 (m, 10H), 3.34 (s, 3H), 
1.67 (s, 3H), 1.57 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.2, 169.6, 139.9, 132.1, 89.6, 81.1, 
72.4, 71.1, 71.0, 71.0, 69.3, 65.0, 59.5, 41.7, 17.7, 15.2; IR νmax/cm-1 1744, 1702, 1397, 1197, 
1102, 790; HRMS (ESI) calcd for C16H25NNaO8 [M+Na]+ 382.1472, found 382.1473. 
2-[2-(2-Methoxyethoxy)ethoxy]ethyl 2-{1,4,8-trimethyl-6-oxo-2,3-dioxa-5-azabicyclo[2.2.2]  
oct-7-en-5-yl}acetate 22. Pyridone 16 (40 mg, 0.13 mmol) flash chromatography (20:1 
DCM/MeOH v/v) yielded the endoperoxide 22 as a clear oil (31 mg, 0.08 mmol, 95%), purity 
>90%. 
1H NMR (300 MHz, CDCl3) δ 6.08 – 6.04 (m, 1H), 4.71 (d, J = 18.3 Hz, 1H), 4.37 – 4.19 (m, 
2H), 3.92 (d, J = 18.3 Hz, 1H), 3.76 – 3.48 (m, 10H), 3.38 (s, 3H), 1.97 (d, J = 1.8 Hz, 3H), 1.64 
(s, 3H), 1.56 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.1, 169.5, 148.1, 125.7, 91.4, 80.8, 72.1, 
71.9, 70.7, 68.9, 64.7, 59.2, 59.1, 41.3, 16.2, 15.1, 14.9; IR νmax/cm-1 1745, 1703, 1397, 1194, 
1096; HRMS (ESI) calcd for C17H27NNaO8 [M+Na]+ 396.1630, found 396.1631. 
 
Statistics. For data analysis GraphPad Prism 5.04 software was used and all data were expressed 
as mean and standard error of the mean. To determine the differences between the different 
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conditions one-way respectively two-way analysis of variance (ANOVA) with a Bonferroni 
posthoc test was performed for the numeric data. A p value of <0.05 was considered significant. 
* denotes p < 0.05, ** denotes p < 0.01, *** denotes p < 0.001, **** denotes p < 0.0001  
 
ASSOCIATED CONTENT 
NMR-Spectra, exponential decay curves and cell micrographs. This material is available free of 
charge via the Internet at http://pubs.acs.org 
 
AUTHOR INFORMATION 
Corresponding Author 
* Dr. Henning Jacob Jessen, University of Zürich, Institute of Organic Chemistry, 
Winterthurerstrasse 190, 8057 Zürich, Switzerland; e-mail: henningjacob.jessen@uzh.ch; phone: 
+41 44 63 5 42 41 
* PD Dr. Dr. Daniel Eberli, University of Zürich, Universitätsspital Zürich, Klinik für Urologie, 
Frauenklinikstrasse 10, 8091 Zürich, Switzerland; e-mail: Daniel.Eberli@usz.ch; phone: +41 44 
255 9619 
Dr. Eberli and Dr. Jessen both serve as last authors. Justification: this work was only possible 
through combination of the distinct knowledge of two research groups (Dr. Eberli – Cellwork, 
Tissue Engineering, Dr. Jessen - Chemistry). 
 
 32 
Present Addresses 
† Professor Jay S. Siegel, Dean; School of Pharmaceutical Science and Technology; Tianjin 
University (A210/Bldg 24); 92 Weijin Road, Nankai District; Tianjin, 300072 PRC 
Author Contributions 
The manuscript was written through contributions of all authors. All authors have given approval 
to the final version of the manuscript. ‡These authors contributed equally.  
Funding Sources 
This work was funded by the Fonds der Chemischen Industrie (FCI, Germany), the Swiss 
National Science Foundation (SNF) and the University of Zürich (UZH). 
Notes 
Normoxic conditions are generally referred to as 21% oxygen, hypoxic conditions 1-5% oxygen 
and anoxic conditions <1% oxygen. It should be noted that most cells behave differently under 
hypoxic conditions found in their respective tissue as compared to normoxia, which is hardly the 
oxygen partial pressures most cells are exposed to. One needs to be aware of the fact that 
normoxia (21% O2) is in fact for most cells a hyperoxic condition and hypoxic conditions are 
actually representative of an in situ normoxia for many cells.51 
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